Comprehensive safety review of GLP-1 receptor agonists for T2DM: main concerns are GI side effects (nausea) that diminish with time, with rare pancreatitis and thyroid C-cell concerns under monitoring.
Key findingComprehensive safety review of GLP-1 receptor agonists for T2DM: main concerns are GI side effects (nausea) that diminish with time, with rare pancrea
What the researchers found
Comprehensive safety review of GLP-1 receptor agonists for T2DM: main concerns are GI side effects (nausea) that diminish with time, with rare pancreatitis and thyroid C-cell concerns under monitoring.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
International journal of clinical practice, 64(10), 1402-14
Citation
Russell-Jones, D. (2010). The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.. International journal of clinical practice, 64(10), 1402-14. https://doi.org/10.1111/j.1742-1241.2010.02465.x